fzd7

SRI 37892 is a Fzd7 inhibitor with potent activities against Wnt/β-catenin signaling and cancer cell viability.

F7H is a potent Frizzled receptor FZD7 antagonist with an IC50 value of 1.25 μM.F7H is a potent ligand for the transmembrane structural domain (TMD) of FZD7, with potential antitumor and bacteriostatic activity.

Fz7-21 ((Ac)-LPSDDLEFWCHVMY-NH2) is a peptide antagonist of FZD7 . It antagonises WNT3A-induced Wnt-β-catenin signalling in HEK293 expressing FZD7. Fz7-21 impairs Wnt/β-catenin signaling in HEK293 cells stimulated with exogenous WNT3A (IC50=100 nM) or transfected with a construct expressing WNT3A or WNT1. Fz7-21 also blocks WNT3A-mediated stabilization of β-catenin in mouse L cells (IC50=50 nM).

Anti-FZD7 Antibody is a human-derived antibody expressed in CHO cells, targeting FZD7. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For an isotype control, refer to [HumanIgG1kappa, Isotype Control].

FZD7 antagonist 1 (peptide 34), a dFz7-21 analogue, inhibits wnt3a with an IC50 of 9.2 nM and blocks TcdB−FZD interaction by targeting FZD receptors [1].

FJ9 is a FZD7 inhibitor which disrupts protein-protein interaction between Frz7 and the PDZ domain of DVL, and induces apoptosis in melanoma cell line and non-small cell lung cancer cell line.

Fz7-21 TFA ((Ac)-LPSDDLEFWCHVMY-NH2 TFA), a peptide antagonist of Frizzled 7 (FZD 7) receptors, selectively binds to FZD7 CRD subclass. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively.